EBV+ polymorphic B-cell lymphoproliferative disorder, NOS: a single-center study of a newly recognized pathologic entity.

ABSTRACT: EBV-positive polymorphic B-cell lymphoproliferative disorder, NOS (poly B-LPD), is a newly defined entity in the 2022 International Consensus Classification of mature lymphoid neoplasms. Its clinical behavior and optimal treatment approach remain poorly characterized. We conducted a retrospective study of 31 patients diagnosed with EBV+ poly B-LPD at Mayo Clinic (2003-2024), excluding transplant recipients. Median age was 56 years; 71% had extranodal involvement, 68% presented with stage III/IV disease, and 52% had autoimmune conditions. Thirty-five percent (n = 11) were on immunosuppressive therapy at diagnosis, all of whom underwent reduction of immunosuppression (RIS); five underwent RIS alone, achieving four complete responses including two with central nervous system (CNS) involvement

SUBMITTER: Atallah-Yunes SA 

PROVIDER: S-EPMC12533106 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature